Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

Launched by NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES, PAKISTAN · Dec 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called Apixaban to see if it can help prevent the formation of blood clots in the heart's left ventricle after a heart attack, specifically in patients who have severe heart dysfunction. The trial compares the effects of low dose Apixaban combined with standard medical treatment against standard treatment alone. It aims to find out which approach is safer and more effective for patients recovering from a heart attack affecting the front wall of the heart.

To participate in this study, individuals need to be between 18 and 65 years old and have recently experienced a specific type of heart attack known as an anterior STEMI, along with serious heart function issues (meaning their heart is not pumping well). Importantly, they should not already have any blood clots in their left ventricle. Participants will receive careful monitoring and treatment during the trial, and they will contribute to important research that could improve care for future heart attack patients. If you or a loved one meet these criteria and are interested, this trial might be a valuable opportunity to consider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18-65 years
• • Presenting with acute anterior STEMI
• • Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm
• • WIHTOUT evidence of LV thrombus.
• Exclusion Criteria:
• • Patients with previous anterior myocardial infarction or LAD revascularization procedures
• • Patients with cardiogenic shock
• • Patients with LV thrombus
• • Patients with advanced CKD (Cr \> 2 and those on hemodialysis)
• • Recent ICH or major bleed requiring transfusion, low platelet counts \<100,000
• • History of recent CVA ( within past three months)
• • Patients with atrial fibrillation or other indications for chronic anticoagulation
• • Pregnant patients and those with hematological disorders